Search company, investor...

Escient

escient.com

About Escient

Provider of audio and video products that meld the power of the Internet seamlessly with intuitive home-entertainment devices. The company's products and services are designed to enhance the entertainment experience by providing ways to access music, movies, and related content throughout the home. It possesses a portfolio of designs for new products including media servers, DVD systems, remote players and networking, and streaming devices, that are brought to market through a channel of over 800 locations throughout the United States, Canada, Europe and Mexico, and in partnership with other global consumer electronics brand. [Keywords: home entertainment*, audio*, video*, media*, internet*]

Headquarters Location

6640 Intech Boulevard Suite 250

Indianapolis, Indiana, 46278,

United States

(317)616-6789

Missing: Escient's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Escient's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Escient News

San Diego biotech lands $120M to launch a slate of trials in neurosensory disorders

Nov 28, 2022

Amber Tong Senior Editor Days af­ter adding some fi­nance, deal­mak­ing and tech­ni­cal tal­ent to the top team, Escient Phar­ma has tak­en the wraps off a $120 mil­lion round to go broad­er in the clin­ic. New En­ter­prise As­so­ci­ates, Abing­worth and Forge Life Sci­ence Part­ners co-led the Se­ries C. The San Diego biotech has been turn­ing a new page. At the be­gin­ning of the year, co-founder Alain Baron stepped down from the CEO post, mak­ing room for Joshua Grass — who brought on a trio of new ex­ecs ear­li­er this month: Aaron Mishel, CFO; David Houck, VP of chem­istry, man­u­fac­tur­ing & con­trols; and Greg Bal­ani, di­rec­tor of busi­ness de­vel­op­ment. As he an­nounced their ap­point­ments, Grass not­ed that Escient plans to start five more clin­i­cal tri­als in 2023. Escient’s spe­cial­ty lies in what it calls neu­rosen­so­ry-in­flam­ma­to­ry dis­or­ders, or chron­ic dis­eases that re­sult from an ex­ces­sive re­sponse to ex­ter­nal stim­uli, with symp­toms rang­ing from itch to al­ler­gy to pain. By hit­ting a class of cell sur­face re­cep­tors known as Mas-re­lat­ed G-pro­tein cou­pled re­cep­tors, or MRG­PRs — which are ex­pressed on sen­so­ry neu­rons and im­mune cells — the com­pa­ny hopes to break the vi­cious cy­cle of neu­ro-im­mune over­re­ac­tion and in­flam­ma­tion. Specif­i­cal­ly, the team is start­ing with two small mol­e­cule can­di­dates. EP262 is an MRG­PRX2 an­tag­o­nist that will be test­ed in chron­ic spon­ta­neous ur­ticaria, chron­ic in­ducible ur­ticaria and atopic der­mati­tis; EP547, an MRG­PRX4 an­tag­o­nist, has al­ready com­plet­ed a healthy vol­un­teers tri­al and is be­ing test­ed for ure­mic pru­ri­tus, thanks to its $77.5 mil­lion Se­ries B two years ago. Escient hopes to start an­oth­er proof-of-con­cept study in cholesta­t­ic pru­ri­tus. In ad­di­tion to help­ing pa­tients re­duce the itch­ing sen­sa­tion, Grass not­ed that Escient is hop­ing its drugs can avoid “the se­ri­ous side ef­fects ob­served with oth­er ap­proach­es.” Join­ing the syn­di­cate for this round are Avego, PFM Health Sci­ences and The Eleven Fund. Ex­ist­ing in­vestors in­clude The Col­umn Group, 5AM Ven­tures, Red­mile Group, Cowen Health­care In­vest­ments, Sanofi Ven­tures, Os­age Uni­ver­si­ty Part­ners, and Al­ti­tude Life Sci­ence Ven­tures. AUTHOR John Carroll Editor & Founder The FDA has gone out of its way several times to flatten any expectations for Spectrum’s lung cancer drug poziotinib, including slamming the regulatory door in the biotech’s face four years ago when the their executive crew came calling for a breakthrough drug designation and encouragement from the oncology wing of the FDA. That stinging early rebuke pointed straight down the path to a corrosive in-house agency review of Spectrum’s attempt to land an accelerated approval for the oral EGFR TKI and a public whipping that included a classic takedown by none other than Richard Pazdur, who slammed the company for “poor drug development” that led to confusion over the dose needed for a slice of NSCLC patients harboring HER2 exon 20 insertion mutations. Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers  can visit their reader profile  to add Endpoints Weekly. New to Endpoints? Sign up here . As you start planning for #JPM23, we hope you will consider joining Endpoints News for our live and virtual events . For those who are celebrating Thanksgiving, we hope you are enjoying the long weekend with loved ones. And if you’re not — we’ll see you next week! Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor About 11 months after his investment firm’s blank check company helped boost EQRx’s cash coffers by about $1.3 billion, Eli Casdin is out from the biotech’s board. The day before Thanksgiving, he told EQRx’s board that he would resign at the end of that day, according to an SEC filing. The decision “was not due to any disagreement with EQRx” relating to the company’s “operations, policies or practices,” as the biotech outlined in the paperwork with the agency. Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter Toward the end of summer, Massachusetts-based CinCor Pharma was riding high with a $225 million raise, touting a positive data readout. But a closer look under the hood has revealed a few hiccups in its Phase II. CinCor on Monday unveiled topline results from its Phase II trial, dubbed HALO, evaluating baxdrostat in patients with uncontrolled hypertension who are taking up to two blood pressure medications. The trial whiffed on its primary endpoint of evaluating change from the “baseline in mean seated” systolic blood pressure (SBP) in the intent-to-treat population in all dosage levels. Read More Kyle LaHucik Associate Editor With the buzz around the Covid-19 mRNA vaccines wearing off, biotechs attempting to create the next generation of messenger RNA therapeutics are in full swing, and MIT-founded Strand Therapeutics has picked up $45 million more to do so. The Boston-based drug developer added that amount to its original $52 million Series A, disclosed in June 2021, to get its first solid tumor mRNA candidate into human trials next year. The BeiGene-partnered startup gathered the Series A1 funds from Eli Lilly, FPV, Potentum Partners, existing backer Playground Global and an “unannounced syndicate.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Escient Frequently Asked Questions (FAQ)

  • Where is Escient's headquarters?

    Escient's headquarters is located at 6640 Intech Boulevard, Indianapolis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.